Mindset Pharma

Psychedelic medicine developer

Mindset Pharma develops psychedelic-inspired investigational medicines for psychiatric and neurological disorders, including psilocybin-based compounds and programs based on DMT and 5-MeO-DMT. Otsuka reports that clinical trials have started for MSP-2020, but the trial phase has not been specified. Mindset Pharma was acquired by Otsuka in 2023 and is now a wholly owned subsidiary. The company is based in Toronto, Ontario, Canada; its candidates are investigational and are not available to buy.

Website

mindsetpharma.com

Mindset Pharma catalog

All products · Psychedelic medicine pipeline

Shop the Mindset Pharma catalog

3 items across 1 shelf

Psychedelic medicine pipeline3 items

• MSP-1014 – Psilocybin prodrugInvestigational
• MSP-2003 – Psilocybin-based backup candidateInvestigational
• MSP-2020 – Psilocybin-based 5-HT2A agonistInvestigational